Reproducibility and usefulness of quantitative apparent diffusion coefficient measurements for predicting program death-ligand 1 expression in nasopharyngeal carcinoma

被引：0
|
作者：
Xi Zhong
Li Li
Jinxue Yin
Yuanlin Chen
Xin Xin
Lanlan Yu
Yongfang Tang
Jiangyu Zhang
Jiansheng Li
机构：
[1] Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Department of Medical Imaging
[2] The Third Affiliated Hospital of Guangzhou Medical University,Department of Otolaryngology
[3] Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Department of Pathology
来源：
Cancer Imaging | / 23卷
关键词：
Nasopharyngeal carcinoma; Programmed death ligand 1; Magnetic resonance imaging; Apparent diffusion coefficients;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma
    An, Hyo Jung
    Ko, Gyung Hyuck
    Lee, Jeong-Hee
    Lee, Jong Sil
    Kim, Dong Chul
    Yang, Jung Wook
    Kim, Min Hye
    Kim, Jin Pyeong
    Jung, Eun Jung
    Song, Dae Hyun
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2018, 52 (01) : 9 - 13
  • [32] Programmed cell death-ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma
    Tomiyama, Eisuke
    Fujita, Kazutoshi
    Hashimoto, Mamoru
    Miyamoto, Hiroshi
    Netto, George J.
    Nonomura, Norio
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (01) : 89 - 90
  • [33] Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma
    Qiao, Pei-Pei
    Tian, Kai-Sai
    Han, Li-Tao
    Ma, Ben
    Shen, Cen-Kai
    Zhao, Run-Yu
    Zhang, Yi
    Wei, Wen-Jun
    Chen, Xiao-Ping
    ENDOCRINE, 2022, 76 (03) : 660 - 670
  • [34] Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration
    Yu, Dan
    Cheng, Jinzhang
    Xue, Kai
    Zhao, Xue
    Wen, Lianji
    Xu, Chengbi
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (04) : 1437 - 1443
  • [35] Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
    Zhu, Jun
    Wen, Hao
    Bi, Rui
    Wu, Yong
    Wu, Xiaohua
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (06)
  • [36] Contrasting Roles of Programmed Death-Ligand 1 Expression in Tumor and Stroma in Prognosis of Esophageal Squamous Cell Carcinoma
    Murakami, Tomohiro
    Booka, Eisuke
    Furuhashi, Satoru
    Sakai, Yuki
    Sekimori, Kenichi
    Haneda, Ryoma
    Fujihiro, Mayu
    Matsumoto, Tomohiro
    Morita, Yoshifumi
    Kikuchi, Hirotoshi
    Hiramatsu, Yoshihiro
    Baba, Satoshi
    Takeuchi, Hiroya
    CANCERS, 2024, 16 (06)
  • [37] Commentary on "Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma"
    Pena-Cardelles, Juan Francisco
    Moro-Rodriguez, Jose Ernesto
    Cebrian-Carretero, Jose Luis
    Pozo-Kreilinger, Jose Juan
    OPEN MEDICINE, 2022, 17 (01): : 227 - 228
  • [38] Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma
    Hongo, Takahiro
    Kuga, Ryosuke
    Miyazaki, Masaru
    Komune, Noritaka
    Nakano, Takafumi
    Yamamoto, Hidetaka
    Koike, Kensuke
    Sato, Kuniaki
    Kogo, Ryunosuke
    Nabeshima, Kazuki
    Oda, Yoshinao
    Nakagawa, Takashi
    LARYNGOSCOPE, 2021, 131 (12): : 2674 - 2683
  • [39] Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma
    Faiena, Izak
    Astrow, Stephanie H.
    Elashoff, David A.
    Jain, Rajul
    Bot, Adrian
    Chamie, Karim
    Belldegrun, Arie S.
    Pantuck, Allan J.
    Drakaki, Alexandra
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (05) : 743 - 751
  • [40] Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma
    Izak Faiena
    Stephanie H. Astrow
    David A. Elashoff
    Rajul Jain
    Adrian Bot
    Karim Chamie
    Arie S. Belldegrun
    Allan J. Pantuck
    Alexandra Drakaki
    Cancer Immunology, Immunotherapy, 2019, 68 : 743 - 751
12345